Načítá se...
Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy
PURPOSE: To compare the outcomes of treatment with intravitreal bevacizumab (IVB) versus observation in central serous chorioretinopathy (CSCR). METHODS: In a retrospective comparative study, records of 45 patients with CSCR were reviewed. Twenty-two patients received IVB (1.25 mg/0.05 ml) while 23...
Uloženo v:
| Vydáno v: | J Ophthalmic Vis Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medknow Publications & Media Pvt Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4860989/ https://ncbi.nlm.nih.gov/pubmed/27195087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2008-322X.180700 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|